Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind, randomized, placebo-controlled phase 3 study of cannabidiol as add-on therapy in tuberous sclerosis complex with inadequately controlled seizures
2015-002154-12Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tuberous sclerosis complex (TSC) and epilepsy comparing Cannabidiol add-on with Placebo add-on (2 arms). Started Jul 2016; status: completed.
02
Drugs
cannabidiol
03
Conditions
tuberous sclerosis complex (TSC)epilepsy
Beyond the preview
Go deeper on 2015-002154-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002154-12.